Loading clinical trials...
Loading clinical trials...
Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines
Conditions
Interventions
64Cu-ATSM
FDG
Locations
2
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
St Louis, Missouri, United States
Start Date
July 29, 2009
Primary Completion Date
December 31, 2011
Completion Date
December 31, 2011
Last Updated
August 14, 2023
NCT06157151
NCT06952660
NCT04895709
NCT05108298
NCT05952141
NCT07276360
Lead Sponsor
American College of Radiology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions